Total Payments
$213,554
2024 Payments
$107,622
Companies
4
Transactions
65
Payment Breakdown by Category
Research$190,026 (89.0%)
Consulting$12,710 (6.0%)
Other$5,078 (2.4%)
Travel$4,761 (2.2%)
Food & Beverage$980.48 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $190,026 | 36 | 89.0% |
| Consulting Fee | $12,710 | 6 | 6.0% |
| Honoraria | $5,078 | 1 | 2.4% |
| Travel and Lodging | $4,761 | 11 | 2.2% |
| Food and Beverage | $980.48 | 11 | 0.5% |
Payments by Type
Research
$190,026
36 transactions
General
$23,529
29 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine BioSciences Inc. | $201,836 | 56 | $0 (2024) |
| Eton Pharmaceuticals, Inc. | $6,078 | 3 | $0 (2023) |
| PFIZER INC. | $5,569 | 5 | $0 (2024) |
| Lilly USA, LLC | $71.76 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $107,622 | 15 | Neurocrine BioSciences Inc. ($103,662) |
| 2023 | $95,379 | 36 | Neurocrine Biosciences, Inc. ($93,270) |
| 2022 | $500.00 | 1 | Eton Pharmaceuticals, Inc. ($500.00) |
| 2021 | $5,246 | 3 | Eton Pharmaceuticals, Inc. ($5,078) |
| 2019 | $2,750 | 2 | Neurocrine Biosciences, Inc. ($2,750) |
| 2018 | $1,986 | 7 | Neurocrine Biosciences, Inc. ($1,986) |
| 2017 | $71.76 | 1 | Lilly USA, LLC ($71.76) |
All Payment Transactions
65 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $5,352.26 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 11/19/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $6,487.69 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 11/19/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $2,888.26 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 11/19/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $1,610.68 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 10/22/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $2,099.31 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 09/16/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $3,253.93 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 07/09/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $8,122.78 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 07/01/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $23,853.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 07/01/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $5,716.40 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 06/10/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $20,212.49 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 06/10/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $5,020.44 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 04/22/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $15,163.32 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 03/22/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $1,459.86 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 03/19/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $2,421.45 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 02/29/2024 | PFIZER INC. | NGENLA (Drug) | Consulting Fee | Cash or cash equivalent | $3,960.00 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 12/18/2023 | Neurocrine BioSciences, Inc. | — | — | Cash or cash equivalent | $2,984.28 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 12/12/2023 | Neurocrine BioSciences, Inc. | — | — | Cash or cash equivalent | $3,621.91 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 11/20/2023 | Neurocrine BioSciences, Inc. | — | — | Cash or cash equivalent | $7,581.64 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 11/19/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $826.32 | General |
| 11/19/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $454.76 | General |
| 11/19/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $166.97 | General |
| 11/19/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $160.89 | General |
| 11/16/2023 | Neurocrine BioSciences, Inc. | — | — | Cash or cash equivalent | $1,755.45 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 11/10/2023 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 10/09/2023 | Neurocrine BioSciences, Inc. | — | — | Cash or cash equivalent | $539.66 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | Neurocrine BioSciences Inc. | $54,488 | 9 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | Neurocrine BioSciences Inc. | $49,174 | 5 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | Neurocrine BioSciences, Inc. | $48,700 | 11 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | Neurocrine BioSciences, Inc. | $37,515 | 10 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN PEDIATRIC SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | Neurocrine Biosciences, Inc. | $148.50 | 1 |
About Dr. Patricia Fechner, MD
Dr. Patricia Fechner, MD is a Pediatric Endocrinology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1720063902.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patricia Fechner, MD has received a total of $213,554 in payments from pharmaceutical and medical device companies, with $107,622 received in 2024. These payments were reported across 65 transactions from 4 companies. The most common payment nature is "" ($190,026).
Ad
Practice Information
- Specialty Pediatric Endocrinology
- Location Seattle, WA
- Active Since 12/12/2005
- Last Updated 07/10/2012
- Taxonomy Code 2080P0205X
- Entity Type Individual
- NPI Number 1720063902
Products in Payments
- Alkindi (Drug) $5,078
- NGENLA (Drug) $3,960
- ALKINDI (Drug) $1,000
- HUMATROPE (Drug) $71.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Endocrinology Doctors in Seattle
Dr. Melinda Pierce, Md, MD
Pediatric Endocrinology — Payments: $3,097
Pediatric Endocrinology $3,097
Ak Helen Dichek, Md, MD
Pediatric Endocrinology — Payments: $2,613
Pediatric Endocrinology $2,613
Alissa Roberts, M.d, M.D
Pediatric Endocrinology — Payments: $662.27
Pediatric Endocrinology $662.27
Meenal Gupta, Md, MD
Pediatric Endocrinology — Payments: $365.00
Pediatric Endocrinology $365.00
David Werny, Md, Mph, MD, MPH
Pediatric Endocrinology — Payments: $282.27
Pediatric Endocrinology $282.27
Isabella Niu, M.d, M.D
Pediatric Endocrinology — Payments: $262.41
Pediatric Endocrinology $262.41